Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Ingelheim Expands Oncolytic Virus Efforts With ViraTherapeutics Buy

Executive Summary

Paying €210m for a company that only has preclinical programs may seem steep but BI is clearly impressed with the progress being made by its Austrian partner's lead candidate.

Advertisement

Related Content

Deal Watch: Cigna Acquisition Of Express Scripts OKed By US Justice Dept.
Transgene Hopes To Finally Catch The Wave In Virus Based Immunotherapies
Deal Watch: Gilead’s Immunology Collaboration With Verily Continues Pivot Away From Virology
Merck & Co's Viralytics Buy Puts Oncolytic Viruses Back In Spotlight
PsiOxus Will Seek $50m Series D Financing In H1 2018 To Fund Pipeline
Rigontec Buy Adds RNA Tech To Merck & Co IO Portfolio
GSK bolsters vaccine business with Merck cast-off

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123834

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel